Navigation Links
Sanofi-aventis Announces Second Quarter 2009 Results
Date:7/29/2009

uld provide significant scope for value creation through external growth opportunities targeting a return above cost of capital.

(6) Before the impact of inflation and any significant change to the activities of the Group, at constant exchange rates

Research and Development

During the second quarter of 2009, initiatives continued to transform the Group's Research and Development operations, with a view to continuing to refocus on innovation, gaining flexibility, and reorienting some of its existing resources to external collaborations.

On April 29, 2009, the results of the complete, in-depth review of the R&D portfolio conducted as part of the sanofi-aventis transformation program were announced. The main changes in the portfolio since that date are:

  • 4 new candidates entered Phase I:
    • SAR548304 (biliary acid reabsorption inhibitor), developed for hypercholesterolemia, and SAR153192, an anti-DLL4 monoclonal antibody developed for cancer
    • XL147 (orally-administered PI3K inhibitor) and XL765 (orally-administered double PI3K and target mTOR inhibitor), developed for cancer: sanofi-aventis has obtained an exclusive world license for both of these products, which were developed by the biotechnology company Exelixis
  • SAR 407899, a rho-kinase inhibitor, entered Phase II in erectile dysfunction.
  • BSI-201, a PARP inhibitor, developed by BiPar Sciences (recently acquired by sanofi-aventis) entered Phase III in July. This pivotal study will evaluate the product in association with chemotherapy in women with metastatic triple negative breast cancer (mTNBC), i.e. with a tumor that expresses neither the estrogen receptor nor the progesterone receptor and does not over-express the HER2 receptor.
  • Enrolment to the Phase III study, evaluating NV1FGF in critical ischemia of t
    '/>"/>

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet(R)
2. Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
3. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
4. ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time
5. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
6. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
7. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
8. Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
9. Sanofi-aventis U.S. Announces Settlement of Medicaid Best Price Investigation
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ... independent team of researchers from South ... (TB4) plays an important role in accelerating the ... an experimental mouse model, by promoting blood vessel ... dermal tissue.  The research found that the underlying ...
(Date:5/4/2015)... Achieved primarily through a proprietary paraffin and stain additive, ... better detail than the industry standard. But because ... methods, it needed another medium to measure its detail. ... reference because it represents the highest standard of detail ... discovery days of Ultralight Histology was to reverse engineer ...
(Date:5/4/2015)... HONG KONG , May 4, 2015 ... or the "Company"), China,s leading ... cell processing and stem cell storage services, today announced ... Holdings Limited ("Golden Meditech"), a Hong Kong ... the Company, has entered into an agreement (the "Agreement") ...
(Date:5/4/2015)... , May 4, 2015   Tocagen Inc. ... interim data from Tocagen,s ongoing investigational studies were ... of the American Association of Neurological Surgeons (AANS)/Congress ... May 1-2, 2015, in Washington, D.C. ... held a meeting with FDA and continues to ...
Breaking Biology Technology:Researchers Report that Thymosin B4 has a Major Role in Dermal Burn Wound Healing 2Researchers Report that Thymosin B4 has a Major Role in Dermal Burn Wound Healing 3China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 2China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 2Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 5
... Texas, June 22, 2011 Five exceptional oncology ... McKesson Specialty Care Solutions | US Oncology ... their patients. The Excellence in Oncology Nursing Award honors those ... who exemplify competency, courage and determination in providing the highest ...
... June 22, 2011 The Roche manuscript: "Immunoglobulin Domain ... Bispecific IgG Antibodies" has been published in the prestigious ... USA (PNAS). Corresponding authors are Wolfgang Schaefer, ... and Christian Klein, Head of Oncology Programs, Discovery Oncology ...
... June 22, 2011 VENENUM Biodesign, a drug discovery ... compound collection to identify potential therapeutic agents against its ... that it opened its new medicinal chemistry space at ... The facility comprises over 11,000 square feet of ...
Cached Biology Technology:McKesson Specialty Care Solutions | US Oncology Honors Five Exceptional Oncology Nurses for Outstanding Work 2McKesson Specialty Care Solutions | US Oncology Honors Five Exceptional Oncology Nurses for Outstanding Work 3McKesson Specialty Care Solutions | US Oncology Honors Five Exceptional Oncology Nurses for Outstanding Work 4Proceedings of the National Academy of Sciences (PNAS) Publishes Roche Manuscript on Production of Bispecific IgG Antibodies 2VENENUM Biodesign Announces Opening of Medicinal Chemistry Labs 2
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
(Date:3/31/2015)...  Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant ... Defined Network Architecture (ET Software DNA® 2.0) platforms and ... $20.4 million for the year ended December 31, 2014 ... year ended December 31, 2013. At ... its multi-year transition away from its legacy landline business ...
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... the "Global Iris Recognition Market 2015-2019" report ... Global Iris Recognition market to grow at a CAGR ... This report covers the present scenario and the growth ... period 2015-2019. To calculate the market size, the report ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... disabilities who are struggling to regain the use of ... engineers and students from Rochester Institute of Technology. ... the human body, to improve the performance of external ... disabilities, such as strokes or major spinal cord injuries, ...
... know all there is to know about Escherichia coli, ... has more than four thousand genes, and the functions ... Siegele, a biology professor at Texas A&M University whose ... , Harmless E. coli strains are normally found in ...
... Understanding, through its Institute for Arctic Studies, has ... Science Foundation through its Integrative Graduate Education and ... grant supports the development of an interdisciplinary doctoral ... a focus on rapid environmental change. "This grant ...
Cached Biology News:Robotics research: Enhancing the lives of people with disabilities 2GIANT-Coli: A novel method to quicken discovery of gene function 2Dartmouth awarded NSF grant for new polar sciences, engineering grad program 2Dartmouth awarded NSF grant for new polar sciences, engineering grad program 3
SHEEP ANTI FLECAINIDE...
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
Sterile glass 5 mm beads that make spreading bacterial and yeast cultures easy. Can be washed, autoclaved and reused....
REGULATED IN DEVELOPMENT AND DNA DAMAGE RESPONSES 1,HIF-1 responsive RTP801...
Biology Products: